Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Endometriosis pain relief: letrozole takes on danazol in new study

NCT ID NCT07183787

Symptom relief Sponsor: Sidra Salman Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested two drugs, letrozole and danazol, to see which better reduces pelvic pain in women with endometriosis. Sixty women aged 18-45 with moderate to severe pain took one of the two drugs daily for 12 weeks. The main goal was to measure changes in pain scores, with the hope of finding a more effective or better-tolerated treatment option.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Letrozole (2.5 mg daily) and danazol (200 mg twice daily), both taken orally for 12 weeks.
What this could lead to
If letrozole works as well as or better than danazol, it could offer a new, possibly better-tolerated option for managing endometriosis pain.
What could go wrong
This is a small, phase 2 study with only 60 participants, so results may not apply to everyone. Both drugs have side effects, and the study doesn't show long-term safety or effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

Apr 2019

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged 18-45 years Surgically or clinically diagnosed endometriosis Moderate to severe pelvic pain (NRS ≥ 4 for at least 3 months) Willing to use effective contraception during the study Able to provide informed consent Exclusion Criteria: * Pregnant or breastfeeding Severe hepatic disease, thromboembolic disorder, or contraindication to study drugs Use of hormonal therapy within the last 8 weeks Known hypersensitivity to Letrozole or Danazol Participation in another clinical trial within the last 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometriosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometriosis

Contacts and locations

Locations

  • Sharif Medical and Dental College

    Lahore, Punjab Province, 54700, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.